Alameda, United States
Exelixis, a pioneering entity in the Biotechnology industry, has been transforming the landscape of cancer treatment since its inception in 1994. Headquartered in the United States, the company operates with a fundamental commitment encapsulated in its slogan: "Exelixis works on discovering, developing, and commercializing therapies for the treatment of cancer."
With nearly three decades of experience, Exelixis has evolved into a multi-platform cancer company renowned for its innovative drug discovery and commercialization strategies. Noteworthy is their flagship product's success, which has underpinned their journey towards the next-generation cancer treatments. Exelixis prides itself on its resilient track record and its continued commitment to providing hope for cancer patients and their families.
The company's last reported financial move was a substantial $135.00M post-IPO equity investment on 01 July 2015, positioning itself as a robust contender for venture capitalists looking to invest in impactful, science-driven healthcare solutions.
